Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27796360 | 0.98 | HTR1A (0.35) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| Hydrochloric Acid SCHEMBL3710166 | 0.98 | HTR1A (0.35) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| SCHEMBL1137793 | 0.82 | NPC1 (0.53) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| Hydrochloric Acid SCHEMBL1137764 | 0.81 | NPC1 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| Hydrochloric Acid SCHEMBL1429268 | 0.81 | NPC1 (0.51) | HTR1ASLC6A2SLC6A4SLC6A3SLC18A3 | |
| SCHEMBL1429178 | 0.79 | ADORA2A (0.41) | HTR1ASLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL1429519 | 0.78 | ADORA2A (0.40) | HRH3MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL2964295 | 0.78 | ADORA2A (0.40) | HRH3MKNK1MKNK2 | |
| SCHEMBL1428165 | 0.77 | NR1H2 (0.47) | SLC18A3SIGMAR1MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL15310455 | 0.76 | NR1H2 (0.46) | SLC18A3SIGMAR1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8614218-B2 | Fused bicyclic pyrimidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-24 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130310362-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2013-11-21 | — | — | US | disclosed |
| EP-2396331-B1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER IP GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| CN-101778851-B | Fused bicyclic pyrimidines | BAYER SCHERING PHARMA AG | 2013-05-08 | — | — | CN | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2050748-A1 | Novel fused pyrimidines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009021992-A2 | FUSED BICYCLIC PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| CN-101242834-A | Inhibitors of AKT activity | MERCK & CO INC (US) | 2008-08-13 | — | — | CN | disclosed |
| EP-1827436-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006065601-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287457-A1 | Inhibitors of Akt Activity | AKT3, MTOR, STK3 | HTR1A 3886/4885SLC6A2 1809/4885SLC6A4 1607/4885 |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | HTR1A 2865/4885SLC6A2 1777/4885SLC6A4 1397/4885 |
| US-20090137607-A1 | FUSED BICYCLIC PYRIMIDINES | PIK3CA, TYMS, MTOR | HTR1A 2896/4885SLC6A2 2349/4885SLC6A4 1687/4885 |
| US-20130310362-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, PIK3CD | HTR1A 1815/4885SLC6A2 1755/4885SLC6A4 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.